During the year, more than 1,000 listed companies set off a wave of buybacks, and pharmaceutical companies became "frequent customers"

Statistics from flush data show that since the beginning of this year, nearly 200 listed companies in the Hong Kong stock market have set off a wave
of buybacks.
As of October 17, Hong Kong companies have repurchased HK$73 billion during the year, close to twice the total amount of repurchases in 2021 and a record high
.
Judging from the repurchase list, pharmaceutical companies are "regulars"
.
According to industry statistics, in the first quarter of 2022 alone, more than 30 pharmaceutical companies announced share repurchase plans and repurchase progress
.
Not to be outdone, Wind data shows that since 2022, 1,007 A-share listed companies have implemented share repurchases, during which 8.
919 billion shares have been repurchased, with a total repurchase amount of 86.
323 billion yuan
.
As of October 18, a total of 124 listed companies in the A-share Shenwan first-class pharmaceutical biology and beauty care company repurchased 486 million shares, with a total amount of 12.
1 billion yuan
.
In the field of medicine, from the perspective of repurchase amount, Hengrui Pharmaceutical's repurchase amount is the first, with the repurchase amount exceeding 1 billion yuan, reaching 1.
060 billion yuan
.
Mindray followed suit, with a buyback amount approaching RMB1 billion
.
In addition, Yunnan Baiyao, Health Yuan, Kelleying, Changgao Gaoxin, etc.
are also relatively eye-catching, and the repurchase amount is more than
500 million yuan.
In terms of the number of shares repurchased, HealthYuan led with 50.
96 million shares, followed by Jointown, Hengrui Pharmaceutical, China Resources Shuanghe and Tonghua Dongbao, with 36.
14 million shares, 29 million shares, 22.
17 million shares and 20.
31 million shares
respectively.
In addition, Hisun Pharmaceutical, Huahai Pharmaceutical, Dezhan Health, Yingke Medical, Lepu Medical, Yunnan Baiyao, Salubris and Jilin Aodong also repurchased more than 10 million shares
.
In terms of the number of repurchases, WuXi Biologics has been active in repurchases, with a total of eight repurchases in the past month, with a total capital contribution of nearly HK$1 billion and more than 20 million shares repurchased (data as of the market close on October 14).

In the past three months, the cumulative number of shares repurchased was 33.
721 million, accounting for 0.
79%
of the company's issued share capital.
Among them, on October 18, WuXi Biologics announced that the company repurchased 3.
20 million shares on the Hong Kong Stock Exchange on October 18, 2022, costing HKD 159 million, and the average repurchase price was about HKD 49.
75 based on the number and cost of the repurchase, and the highest repurchase price was HKD 50.
45 and the lowest repurchase price was HKD 48.
85 according
to the disclosure 。 JD Health has also repurchased many times, also on the 18th, the company announced that the company repurchased 84,700 shares on the Hong Kong Stock Exchange on October 18, 2022, costing 3.
7782 million Hong Kong dollars, and the average repurchase price is about 44.
58 Hong Kong dollars according to the number and cost of the repurchase; according to the disclosure, the highest repurchase price is 45.
15 Hong Kong dollars and the lowest repurchase price is 43.
70 Hong Kong dollars
.
According to statistics, the cumulative number of shares repurchased by JD Health in the past three months is 5.
6512 million shares, accounting for 0.
18%
of the company's issued share capital.
From the perspective of purpose, most pharmaceutical enterprises repurchase share plans function as internal equity incentives, among which Hengrui Pharmaceutical even mentioned in the repurchase plan that it intends to use 6-1.
2 billion yuan of funds to repurchase shares for employee stock ownership plans or equity incentives
.
Data show that Hengrui Pharmaceutical's revenue in 2021 will be 25.
906 billion yuan, a year-on-year decrease of 6.
59%, and the net profit attributable to shareholders of listed companies will be 4.
530 billion yuan, a year-on-year decrease of 28.
41%.

Entering 2022, the interim report shows that the company's operating income decreased by 23.
08% year-on-year, the net profit attributable to the parent decreased by 20.
55% year-on-year, and the net profit attributable to the company's shareholders after deducting non-recurring profits and losses decreased by 24.
12%
year-on-year.
The main reason is related to
the centralized procurement of drugs.
However, the company has expressed its determination to increase R&D investment, and the cumulative R&D investment in the first half of 2022 reached 2.
909 billion yuan, a year-on-year increase of 12.
74%, and the proportion of R&D investment in sales revenue increased to 28.
44%
year-on-year.
Some analysts believe that the repurchase of shares also represents that the company has confidence in self-growth, and believes that its own stock price is close to the trough rebound window and other good news
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.